| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Reneo Pharmaceuticals, Inc. | Chief Development Officer | Common Stock | 39.6K | $249K | $6.28 | Aug 28, 2023 | Direct |
| Reneo Pharmaceuticals, Inc. | Chief Development Officer | Stock option (right to buy) | 109K | Aug 28, 2023 | Direct | ||
| Structure Therapeutics Inc. | Chief Development Officer | Share option (right to buy) | 82.9K | Sep 18, 2024 | Direct | ||
| Structure Therapeutics Inc. | Chief Development Officer | Ordinary Shares | 67.3K | Sep 18, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | Sep 18, 2024 | 2 | $0 | 4 | Sep 20, 2024 | Chief Development Officer |
| GPCR | Structure Therapeutics Inc. | Sep 18, 2024 | 0 | $0 | 3 | Sep 20, 2024 | Chief Development Officer |
| RPHM | Reneo Pharmaceuticals, Inc. | Aug 28, 2023 | 3 | -$69.9K | 4 | Aug 29, 2023 | Chief Development Officer |
| RPHM | Reneo Pharmaceuticals, Inc. | Dec 9, 2022 | 1 | $0 | 4 | Dec 13, 2022 | Chief Development Officer |
| RPHM | Reneo Pharmaceuticals, Inc. | Nov 12, 2021 | 2 | $0 | 4 | Nov 15, 2021 | Chief Development Officer |
| RPHM | Reneo Pharmaceuticals, Inc. | Oct 11, 2020 | 0 | $0 | 3 | Oct 14, 2021 | Chief Development Officer |